Linked
Quark Pharmaceuticals
View CrunchBase or TradeVibes company information.
|
| Website | http://www.quarkpharma.com/ |
|---|---|
| Location | San Francisco |
| Industry | Healthcare & Pharmaceuticals |
| Revenue | unknown |
| Investment | unknown |
| Growth | unknown |
| Employees | unknown |
“Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the ìBiFARî technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quarkís approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.”
(Source: Quark Pharma)
-
News: AsiaNet Daily Summary - Press Releases for Friday, Sept 26, 2008
-
News: Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
-
News: Given Imaging chair Makov to head biomed investment fund
-
News: Given chair Makov to head biomed investment fund
-
News: Quark's partner Pfizer initiates dosing in Phase II DME trial
-
News: Quark Pharmaceuticals Announces First Patient Dosing By Pfizer In Phase II Trial Of RNAi Therapy In Diabetic Macular ...
-
News: My Pharmiweb.com
-
News: (AFX UK Focus) 2008-07-30 17:05 UK small caps close just off session high; Business Direct soars on sale plan
-
News: (AFX UK Focus) 2008-07-30 12:32 Silence Therapeutics to receive $1.9 mln milestone payment from Quark
-
News: Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
